<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39289865</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>18</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1643-3750</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><PubDate><Year>2024</Year><Month>Sep</Month><Day>18</Day></PubDate></JournalIssue><Title>Medical science monitor : international medical journal of experimental and clinical research</Title><ISOAbbreviation>Med Sci Monit</ISOAbbreviation></Journal><ArticleTitle>Long COVID or Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) and the Urgent Need to Identify Diagnostic Biomarkers and Risk Factors.</ArticleTitle><Pagination><StartPage>e946512</StartPage><MedlinePgn>e946512</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.12659/MSM.946512</ELocationID><Abstract><AbstractText>Long COVID, or post-acute sequelae of SARS-CoV-2 infection (PASC), also known as post-COVID-19 condition or post-COVID syndrome, can affect anyone infected with SARS-CoV-2, regardless of age or the severity of the initial symptoms of COVID-19. Long COVID/PASC is the continuation or development of new symptoms after three months from the initial SARS-CoV-2 infection, which lasts for at least two months and has no other identifiable cause. Long COVID/PASC occurs in 10-20% of patients infected with SARS-CoV-2. The most common symptoms include fatigue, cognitive impairment (brain fog), and shortness of breath. However, more than 200 symptoms have been reported. No phenotypic or diagnostic biomarkers have been identified for developing long COVID/PASC, which is a multisystem disorder that can present with isolated or combined respiratory, hematological, immunological, cardiovascular, and neuropsychiatric symptoms. There is no cure. Therefore, individualized patient management requires a multidisciplinary clinical approach. Because millions of people have had and continue to have COVID-19, even in the era of vaccination and antiviral therapies, long COVID/PASC is now and will increasingly become a health and economic burden that the world must prepare for. Almost five years from the beginning of the COVID-19 pandemic, this article aims to review what is currently known about long COVID/PASC, the anticipated increasing global health burden, and why there is still an urgent need to identify diagnostic biomarkers and risk factors to improve prevention and treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Parums</LastName><ForeName>Dinah V</ForeName><Initials>DV</Initials><AffiliationInfo><Affiliation>Science Editor, Medical Science Monitor, International Scientific Information, Inc., Melville, NY, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Med Sci Monit</MedlineTA><NlmUniqueID>9609063</NlmUniqueID><ISSNLinking>1234-1010</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="Y">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004417" MajorTopicYN="N">Dyspnea</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005221" MajorTopicYN="N">Fatigue</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="Y">Post-Acute COVID-19 Syndrome</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of interest:</b> None declared</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>18</Day><Hour>1</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39289865</ArticleId><ArticleId IdType="pmc">PMC11418572</ArticleId><ArticleId IdType="doi">10.12659/MSM.946512</ArticleId><ArticleId IdType="pii">946512</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Centers for Disease Control and Prevention (CDC) Long COVID. 2024.  Available from:  https://www.cdc.gov/covid/long-term-effects/</Citation></Reference><Reference><Citation>World Health Organization (WHO) Coronavirus disease (COVID-19): Post COVID-19 condition. Mar 28, 2023.  Available from:  https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-post-covid-19-condition.</Citation></Reference><Reference><Citation>World Health Organization (WHO) Coronavirus (COVID-19) dashboard. Aug 18, 2024.  Available from:  Https://data.who.int/dashboards/covid19/cases.</Citation></Reference><Reference><Citation>Parums DV. Editorial: Post-acute sequelae of SARS-CoV-2 onfection (PASC). Updated terminology for the long-term effects of COVID-19. Med Sci Monit. 2023;29:e941595.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10321154</ArticleId><ArticleId IdType="pubmed">37392031</ArticleId></ArticleIdList></Reference><Reference><Citation>Parums DV. Editorial: Long COVID, or post-COVID syndrome, and the global impact on health care. Med Sci Monit. 2021;27:e933446.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8194290</ArticleId><ArticleId IdType="pubmed">34092779</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: Major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Parums DV. Editorial: Long-term effects of symptomatic and asymptomatic SARS-CoV-2 infection in children and the changing pathogenesis of common childhood viruses driven by the COVID-19 pandemic. Med Sci Monit. 2022;28:e937927.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9354561</ArticleId><ArticleId IdType="pubmed">35909366</ArticleId></ArticleIdList></Reference><Reference><Citation>Gross R, Lo Re Disentangling the postacute sequelae of SARS-CoV-2: E Unibus Pluram (from one, many) JAMA. 2023;329(22):1918&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">37227710</ArticleId></ArticleIdList></Reference><Reference><Citation>Parums DV. Editorial: Multisystem inflammatory syndrome in adults (MIS-A) and the spectrum of COVID-19. Med Sci Monit. 2021;27:e935005.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8518511</ArticleId><ArticleId IdType="pubmed">34629462</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Mahoney LL, Routen A, Gillies C, et al. The prevalence and long-term health effects of long COVID among hospitalised and non-hospitalised populations: A systematic review and meta-analysis. EClinicalMedicine. 2022;55:101762.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9714474</ArticleId><ArticleId IdType="pubmed">36474804</ArticleId></ArticleIdList></Reference><Reference><Citation>Choutka J, Jansari V, Hornig M, Iwasaki A. Unexplained post-acute infection syndromes. Nat Med. 2022;28(5):911&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">35585196</ArticleId></ArticleIdList></Reference><Reference><Citation>Punsoni M, Lakis NS, Mellion M, de la Monte SM. Post-polio syndrome revisited. Neurol Int. 2023;15(2):569&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10123742</ArticleId><ArticleId IdType="pubmed">37092507</ArticleId></ArticleIdList></Reference><Reference><Citation>Dourmashkin RR. What caused the 1918&#x2013;30 epidemic of encephalitis lethargica? J R Soc Med. 1997;90(9):515&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1296535</ArticleId><ArticleId IdType="pubmed">9370993</ArticleId></ArticleIdList></Reference><Reference><Citation>DeLong A, Hsu M, Kotsoris H. Estimation of cumulative number of post-treatment Lyme disease cases in the US, 2016 and 2020. BMC Public Health. 2019;19(1):352.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6480773</ArticleId><ArticleId IdType="pubmed">31014314</ArticleId></ArticleIdList></Reference><Reference><Citation>Wohl DA, Fischer WA, Mei W, et al. Post-ebola symptoms 7 years after infection: the natural history of long ebola. Clin Infect Dis. 2023;76(3):e835&#x2013;e40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10169389</ArticleId><ArticleId IdType="pubmed">36065768</ArticleId></ArticleIdList></Reference><Reference><Citation>Litleskare S, Rortveit G, Eide GE, et al. Prevalence of irritable bowel syndrome and chronic fatigue 10 years after giardia infection. Clin Gastroenterol Hepatol. 2018;16(7):1064&#x2013;1072e4.</Citation><ArticleIdList><ArticleId IdType="pubmed">29378314</ArticleId></ArticleIdList></Reference><Reference><Citation>The National Institutes of Health (NIH) Researching COVID to enhance recovery (RECOVER)  Available from:  https://recovercovid.org.</Citation></Reference><Reference><Citation>Thaweethai T, Jolley SE, Karlson EW, et al. RECOVER Consortium. Development of a definition of postacute sequelae of SARS-CoV-2 infection. JAMA. 2023;329(22):1934&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10214179</ArticleId><ArticleId IdType="pubmed">37278994</ArticleId></ArticleIdList></Reference><Reference><Citation>Reese JT, Blau H, Casiraghi E, et al. N3C Consortium; RECOVER Consortium. Generalisable long COVID subtypes: Findings from the NIH N3C and RECOVER programmes. EBioMedicine. 2023;87:104413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9769411</ArticleId><ArticleId IdType="pubmed">36563487</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutler DM. The costs of long COVID. JAMA Health Forum. 2022;3(5):e221809.</Citation><ArticleIdList><ArticleId IdType="pubmed">36219031</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao S, Gross RS, Mohandas S, et al. Postacute sequelae of SARS-CoV-2 in children. Pediatrics. 2024;153(3):e2023062570.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10904902</ArticleId><ArticleId IdType="pubmed">38321938</ArticleId></ArticleIdList></Reference><Reference><Citation>Gross RS, Thaweethai T, Kleinman LC, et al. Characterizing long COVID in children and adolescents. JAMA. 2024;21:e2412747.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11339705</ArticleId><ArticleId IdType="pubmed">39196964</ArticleId></ArticleIdList></Reference><Reference><Citation>Gross RS, Thaweethai T, Rosenzweig EB, et al. RECOVER-Pediatric Consortium. Researching COVID to enhance recovery (RECOVER) pediatric study protocol: Rationale, objectives and design. PLoS One. 2024;19(5):e0285635.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11075869</ArticleId><ArticleId IdType="pubmed">38713673</ArticleId></ArticleIdList></Reference><Reference><Citation>Zang C, Zhang Y, Xu J, et al. Data-driven analysis to understand long COVID using electronic health records from the RECOVER initiative. Nat Commun. 2023;14(1):1948.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10080528</ArticleId><ArticleId IdType="pubmed">37029117</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill EL, Mehta HB, Sharma S, et al. N3C Consortium; and the RECOVER Consortium. Risk factors associated with post-acute sequelae of SARS-CoV-2: An N3C and NIH RECOVER study. BMC Public Health. 2023;23(1):2103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10601201</ArticleId><ArticleId IdType="pubmed">37880596</ArticleId></ArticleIdList></Reference><Reference><Citation>Parums DV. Editorial: Cardiovascular complications at one year after SARS-CoV-2 infection are independent of underlying cardiovascular risk factors or severity of COVID-19. Med Sci Monit. 2022;28:e937048.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9069970</ArticleId><ArticleId IdType="pubmed">35490309</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson CB, Farzan M, Chen B, Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol. 2022;23(1):3&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8491763</ArticleId><ArticleId IdType="pubmed">34611326</ArticleId></ArticleIdList></Reference><Reference><Citation>South AM, Diz DI, Chappell MC. COVID-19, ACE2, and the cardiovascular consequences. Am J Physiol Heart Circ Physiol. 2020;318:H1084&#x2013;H1090.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7191628</ArticleId><ArticleId IdType="pubmed">32228252</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu JQ, Lu JY, Wang W, et al. Clinical predictors of acute cardiac injury and normalization of troponin after hospital discharge from COVID-19. EBioMedicine. 2022;76:103821.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8819639</ArticleId><ArticleId IdType="pubmed">35144887</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022;28(3):583&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8938267</ArticleId><ArticleId IdType="pubmed">35132265</ArticleId></ArticleIdList></Reference><Reference><Citation>Erlandson KM, Geng LN, Selvaggi CA, et al. RECOVER-Adult Cohort. Differentiation of prior SARS-CoV-2 infection and postacute sequelae by standard clinical laboratory measurements in the RECOVER cohort. Ann Intern Med. 2024 Aug 13; doi: 10.7326/M24-0737. [Online ahead of print]</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M24-0737</ArticleId><ArticleId IdType="pmc">PMC11408082</ArticleId><ArticleId IdType="pubmed">39133923</ArticleId></ArticleIdList></Reference><Reference><Citation>McCorkell L, Peluso MJ. Long COVID research risks losing momentum &#x2013; we need a moonshot. Nature. 2023;622:457&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">37853144</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal AD, VanElzakker MB, Aleman S, et al. SARS-CoV-2 reservoir in post-acute sequelae of COVID-19 (PASC) Nat Immunol. 2023;24(10):1616&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">37667052</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute for Health and Care Excellence (NICE) UK. [NG188]. COVID-19 rapid guideline: Managing the long-term effects of COVID-19.  Updated 25 January 2024. Available from:  https://www.nice.org.uk/guidance/ng188.</Citation><ArticleIdList><ArticleId IdType="pubmed">33555768</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>